bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of bluebird bio (NASDAQ: BLUE) after Mast Therapeutics' (NASDAQ: MSTX) phase III study (EPIC) of vepoloxamer failed to show efficacy over the placebo.
The analyst considered the problem of what could be done to treat the pain and determined that a cure (via gene therapy) may be the best method. Gene therapy with bluebird's LentiGlobin in just two patients has suggested that targeting the "source" of disease could potentially represent a "cure." The question now is how many patients represent proof of concept (POC), and would the sickle cell community adopt gene therapy? Answering the question will take more patients and more time but the analyst is expecting data from multiple patients at ASH in December.
No change to the price target of $85.
Shares of bluebird bio closed at $73.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PayPal (PYPL) PT Raised to $47 at Credit Suisse; Results Just 'Ok' But Visability Increases Conviction
- Maxim Integrated (MXIM) PT Bumped to $45 at Jefferies Following In-Line Results on Note 7 Impact
- Wedbush Reiterates Outperform on Pool Corp. (POOL) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesMaxim Group
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!